Corcept Therapeutics (CORT) News Today $51.83 -2.96 (-5.40%) (As of 11/15/2024 ET) Add Compare Share Share Headlines Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends All Sources Trusted Sources MarketBeat.com Benzinga Bloomberg GuruFocus MarketWatch Motley Fool NASDAQ PR Newswire Reuters Seeking Alpha The Street TipRanks The Wall Street Journal Yahoo Finance Source Sentiment refers to the positivity or negativity of each headline according to our language processing algorithm. Sentiment All Sentiments Very Positive Positive Neutral Negative Very Negative Most Recent November 2024 October 2024 September 2024 August 2024 July 2024 June 2024 May 2024 April 2024 March 2024 February 2024 January 2024 December 2023 November 2023 October 2023 September 2023 August 2023 July 2023 June 2023 May 2023 April 2023 March 2023 February 2023 January 2023 December 2022 November 2022 October 2022 September 2022 August 2022 July 2022 June 2022 May 2022 April 2022 March 2022 February 2022 January 2022 December 2021 Time Period Cornercap Investment Counsel Inc. Has $426,000 Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Cornercap Investment Counsel Inc. cut its position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 59.9% during the 3rd quarter, according to the company in its most recent disclosure with the SEC. The firm owned 9,212 shares of the biotechnology company's stock after selling 13November 17 at 5:16 AM | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Recommendation of "Buy" by AnalystsNovember 17 at 2:59 AM | americanbankingnews.comRoyce & Associates LP Has $16.81 Million Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Royce & Associates LP lifted its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 3.7% in the 3rd quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 363,272 shares of the biotechnolNovember 16 at 7:17 AM | marketbeat.comIntellectus Partners LLC Purchases Shares of 54,859 Corcept Therapeutics Incorporated (NASDAQ:CORT)Intellectus Partners LLC acquired a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the third quarter, according to its most recent filing with the Securities and Exchange Commission. The institutional investor acquired 54,859 shares of the biotechnology company'sNovember 15 at 7:58 AM | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Principal Financial Group Inc.Principal Financial Group Inc. lessened its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 4.0% during the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 495,658 shares of the biotechnology companyNovember 14 at 3:20 AM | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Receives Average Rating of "Buy" from AnalystsShares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) have received an average recommendation of "Buy" from the five research firms that are presently covering the company, MarketBeat reports. Five investment analysts have rated the stock with a buy recommendation. The averagNovember 12, 2024 | marketbeat.comVersor Investments LP Buys Shares of 24,800 Corcept Therapeutics Incorporated (NASDAQ:CORT)Versor Investments LP bought a new stake in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the 3rd quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The fund bought 24,800 shares of the biotechnology company's stock, valued atNovember 12, 2024 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Stock Holdings Increased by Lisanti Capital Growth LLCLisanti Capital Growth LLC grew its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 79.6% during the third quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The fund owned 113,155 shares of the bioteNovember 11, 2024 | marketbeat.comCWA Asset Management Group LLC Takes $963,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)CWA Asset Management Group LLC bought a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) during the third quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm bought 20,800 shares of the biotechnology cNovember 11, 2024 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Robeco Institutional Asset Management B.V.Robeco Institutional Asset Management B.V. decreased its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 66.6% in the 3rd quarter, according to its most recent Form 13F filing with the SEC. The firm owned 6,436 shares of the biotechnology company's stock afterNovember 11, 2024 | marketbeat.comUS Bancorp DE Raises Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)US Bancorp DE raised its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 162.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The fund owned 19,683 shares of the biotechnology company'sNovember 9, 2024 | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) Stock Price Up 8.9% - Time to Buy?Corcept Therapeutics (NASDAQ:CORT) Shares Up 8.9% - Still a Buy?November 8, 2024 | marketbeat.comM&G Plc Takes $11.17 Million Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)M&G Plc acquired a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the third quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund acquired 242,901 shares of the biotechnology company's stock, valued at approximatelyNovember 8, 2024 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Insider Sells $166,204.18 in StockNovember 6, 2024 | insidertrades.comNew York State Teachers Retirement System Has $5.76 Million Stock Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)New York State Teachers Retirement System decreased its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 12.2% during the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission (SEC). The institutional investNovember 6, 2024 | marketbeat.comCorcept Stock At New High; Will The Upcoming Regulatory And Clinical Trial Catalysts Take It Higher?November 5, 2024 | markets.businessinsider.comRoman Butler Fullerton & Co. Sells 10,466 Shares of Corcept Therapeutics Incorporated (NASDAQ:CORT)Roman Butler Fullerton & Co. reduced its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 65.3% in the 3rd quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 5,565 shares of the biotechnologyNovember 5, 2024 | marketbeat.comTruist Financial Keeps Their Buy Rating on Corcept Therapeutics (CORT)November 4, 2024 | markets.businessinsider.comCorcept Therapeutics (NASDAQ:CORT) Reaches New 1-Year High - Still a Buy?Corcept Therapeutics (NASDAQ:CORT) Reaches New 12-Month High - Here's WhyNovember 4, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for CORT FY2024 Earnings?Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - HC Wainwright increased their FY2024 EPS estimates for shares of Corcept Therapeutics in a report released on Thursday, October 31st. HC Wainwright analyst S. Ramakanth now forecasts that the biotechnology company will post earningsNovember 4, 2024 | marketbeat.comCorcept Therapeutics Third Quarter 2024 Earnings: Beats ExpectationsNovember 3, 2024 | finance.yahoo.comCorcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.2% - Time to Sell?Corcept Therapeutics (NASDAQ:CORT) Stock Price Down 3.2% - Time to Sell?November 1, 2024 | marketbeat.comWhat is HC Wainwright's Forecast for CORT FY2026 Earnings?Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) - Equities research analysts at HC Wainwright boosted their FY2026 EPS estimates for Corcept Therapeutics in a report released on Thursday, October 31st. HC Wainwright analyst S. Ramakanth now anticipates that the biotechnology companyNovember 1, 2024 | marketbeat.comCorcept Therapeutics Inc (CORT) Q3 2024 Earnings Call Highlights: Record Revenue Growth and ...October 31, 2024 | finance.yahoo.comStrong Financial Performance and Promising Clinical Developments Drive Buy Recommendation for Corcept TherapeuticsOctober 31, 2024 | markets.businessinsider.comCorcept Therapeutics price target raised to $73.50 from $72 at LadenburgOctober 31, 2024 | markets.businessinsider.comCorcept Therapeutics (NASDAQ:CORT) Issues Earnings ResultsCorcept Therapeutics (NASDAQ:CORT - Get Free Report) announced its earnings results on Wednesday. The biotechnology company reported $0.41 EPS for the quarter, beating analysts' consensus estimates of $0.27 by $0.14. The business had revenue of $182.55 million during the quarter, compared to analysts' expectations of $171.97 million. Corcept Therapeutics had a return on equity of 23.66% and a net margin of 21.93%. The business's revenue was up 47.7% compared to the same quarter last year. During the same quarter in the prior year, the firm earned $0.28 earnings per share.October 31, 2024 | marketbeat.comHC Wainwright Reiterates Buy Rating for Corcept Therapeutics (NASDAQ:CORT)HC Wainwright restated a "buy" rating and set a $80.00 target price on shares of Corcept Therapeutics in a report on Thursday.October 31, 2024 | marketbeat.comCorcept Therapeutics Reports Strong Revenue and Future PlansOctober 31, 2024 | markets.businessinsider.comabrdn plc Grows Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)abrdn plc increased its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 27.1% during the third quarter, according to its most recent disclosure with the SEC. The institutional investor owned 666,952 shares of the biotechnology company's stock after buying an additionalOctober 31, 2024 | marketbeat.comCorcept Therapeutics Announces Third Quarter Financial Results, Positive Results From Phase 3 GRADIENT Trial in Patients With Cushing's Syndrome and Provides Corporate UpdateOctober 30, 2024 | businesswire.comBoston Trust Walden Corp Reduces Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)Boston Trust Walden Corp reduced its stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 4.4% in the 3rd quarter, according to its most recent disclosure with the Securities and Exchange Commission. The firm owned 1,513,975 shares of the biotechnology company's stockOctober 26, 2024 | marketbeat.comCorcept Therapeutics (CORT) to Release Quarterly Earnings on WednesdayCorcept Therapeutics (NASDAQ:CORT) will be releasing earnings after the market closes on Wednesday, October 30, Zacks reports.October 24, 2024 | marketbeat.comTruist Financial Remains a Buy on Corcept Therapeutics (CORT)October 22, 2024 | markets.businessinsider.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Position Reduced by Exchange Traded Concepts LLCExchange Traded Concepts LLC cut its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 80.7% in the third quarter, according to its most recent disclosure with the Securities and Exchange Commission. The institutional investor owned 14,833 shares of the biotechOctober 19, 2024 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Given Consensus Recommendation of "Buy" by BrokeragesCorcept Therapeutics Incorporated (NASDAQ:CORT - Get Free Report) has earned a consensus recommendation of "Buy" from the five research firms that are presently covering the firm, MarketBeat.com reports. Five research analysts have rated the stock with a buy rating. The average 1-year target priceOctober 18, 2024 | marketbeat.comHC Wainwright Increases Corcept Therapeutics (NASDAQ:CORT) Price Target to $80.00HC Wainwright raised their target price on shares of Corcept Therapeutics from $45.00 to $80.00 and gave the company a "buy" rating in a research note on Friday.October 18, 2024 | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) Sets New 12-Month High - Here's WhyCorcept Therapeutics (NASDAQ:CORT) Hits New 52-Week High - What's Next?October 17, 2024 | marketbeat.comCorcept: Key Announcements Coming SoonOctober 16, 2024 | seekingalpha.comImplied Volatility Surging for Corcept Therapeutics (CORT) Stock OptionsOctober 15, 2024 | msn.comSanctuary Advisors LLC Takes $990,000 Position in Corcept Therapeutics Incorporated (NASDAQ:CORT)Sanctuary Advisors LLC bought a new position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the 2nd quarter, according to its most recent disclosure with the Securities & Exchange Commission. The firm bought 30,466 shares of the biotechnology company's stock, valued at apprOctober 12, 2024 | marketbeat.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Shares Bought by Handelsbanken Fonder ABHandelsbanken Fonder AB raised its holdings in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 60.7% in the 3rd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The firm owned 30,981 shares of the biotechnology cOctober 11, 2024 | marketbeat.comZacks.com featured highlights include Corcept Therapeutics, Abercrombie & Fitch and HCI GroupOctober 10, 2024 | finance.yahoo.comSG Americas Securities LLC Boosts Stake in Corcept Therapeutics Incorporated (NASDAQ:CORT)SG Americas Securities LLC lifted its holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 262.5% during the third quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The institutional investor owned 29,663October 10, 2024 | marketbeat.comMarshall Wace LLP Trims Holdings in Corcept Therapeutics Incorporated (NASDAQ:CORT)Marshall Wace LLP lowered its position in Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 79.5% during the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The fund owned 20,200 shares of the biotechnology companyOctober 9, 2024 | marketbeat.comAlgert Global LLC Invests $412,000 in Corcept Therapeutics Incorporated (NASDAQ:CORT)Algert Global LLC acquired a new stake in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) in the second quarter, according to its most recent filing with the Securities and Exchange Commission. The fund acquired 12,685 shares of the biotechnology company's stock, valued at aOctober 8, 2024 | marketbeat.comCorcept Therapeutics Incorporated's (NASDAQ:CORT) Stock Is Going Strong: Is the Market Following Fundamentals?October 7, 2024 | finance.yahoo.comCorcept Therapeutics (NASDAQ:CORT) Stock, Guidance And ForecastOctober 5, 2024 | benzinga.comCorcept Therapeutics Incorporated (NASDAQ:CORT) Shares Sold by Clearbridge Investments LLCClearbridge Investments LLC reduced its position in shares of Corcept Therapeutics Incorporated (NASDAQ:CORT - Free Report) by 2.0% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission. The institutional investor owned 570,816 shareOctober 5, 2024 | marketbeat.comCorcept Therapeutics (NASDAQ:CORT) Stock, Short Interest ReportOctober 5, 2024 | benzinga.com Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address Buffett’s Selling Out: Is Your 401(k) About to Get Wiped Out? (Ad)Let me share something important with you. Just a few weeks ago, Warren Buffett unloaded $932 million worth of bank stocks. He didn't do it on a whim—he knows something big is coming. The question is: Why aren't you taking action, too? Click Here For Your Free Guide CORT Media Mentions By Week CORT Media Sentiment Learn about the media sentiment score. Each headline receives a score ranging from 2 (good news) to -2 (bad news). Our company news sentiment scores track the average news sentiment of articles about each company over the most recent 7 days in order to identify companies that are receiving positive press. CORT News Sentiment▼1.190.56▲Average Medical News Sentiment CORT News Coverage Learn about the media coverage comparison. We track news headlines from hundreds of news outlets and tag them by company. This chart compares the number of articles about this company in the last seven days compared with the average number of articles about this company on a typical week. CORT Articles This Week▼136▲CORT Articles Average Week Get Corcept Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for CORT and its competitors with MarketBeat's FREE daily newsletter. Email Address Related Companies and Tools Related Companies Axsome Therapeutics News Today Harmony Biosciences News Today Taro Pharmaceutical Industries News Today Xencor News Today OPKO Health News Today ADC Therapeutics News Today Atea Pharmaceuticals News Today Royalty Pharma News Today Jazz Pharmaceuticals News Today Perrigo News Today Headlines Tools Trending Media MentionsHigh Media Sentiment StocksLive News FeedMarketBeat OriginalsStock Ideas This page (NASDAQ:CORT) was last updated on 11/17/2024 by MarketBeat.com Staff From Our PartnersBill Gates’s Next Big AI Bet: StargateIn February 2016… when almost nobody was talking about artificial intelligence…. I picked Nvidia as one of ...Brownstone Research | SponsoredThe Crypto That’s Making Wall Street SweatThe Crypto Wall Street Is Desperate to Hide It's happening now, right under everyone's radar. Big tech gian...Crypto 101 Media | SponsoredThere is a little known company that is changing warfareWith geo - political instability around the world investors are flocking to defense contract stocks. There...Reticulate | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredThe pin that pops the AI bubbleMy new documentary explores the background to this pattern and how and why I believe it will almost certainly ...Porter & Company | Sponsored24/7 Automated Profits in CryptoWhat if you could make consistent daily profits in crypto with minimal effort? Beyond trading lies a vast w...Crypto Swap Profits | SponsoredTrump Wins… But Elon Says Get Ready to BraceTrump's back in the White House, ready to hit the gas on America's comeback. He's taking on the economy wi...Genesis Gold Group | SponsoredMusk’s new company could top a trillion?The investment legend who predicted the rise of Bitcoin, Facebook and streaming services like Netflix… Just...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Corcept Therapeutics Incorporated Please log in to your account or sign up in order to add this asset to your watchlist. Share Corcept Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free CORT Stock Alerts